These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 19860196)
1. [Supportive therapies for myeloid leukemia including blood transfusion and growth factors]. Yao H; Ashihara E; Maekawa T Nihon Rinsho; 2009 Oct; 67(10):1951-7. PubMed ID: 19860196 [TBL] [Abstract][Full Text] [Related]
2. [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. Yokoyama H; Harigae H Nihon Rinsho; 2009 Oct; 67(10):1974-7. PubMed ID: 19860200 [TBL] [Abstract][Full Text] [Related]
3. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081 [TBL] [Abstract][Full Text] [Related]
4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349 [TBL] [Abstract][Full Text] [Related]
6. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Bokemeyer C; Honecker F; Wedding U; Späth-Schwalbe E; Lipp HP; Kolb G; Onkologie; 2002 Feb; 25(1):32-9. PubMed ID: 11893881 [TBL] [Abstract][Full Text] [Related]
7. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Cesaro S; Chinello P; De Silvestro G; Marson P; Picco G; Varotto S; Pittalis S; Zanesco L Support Care Cancer; 2003 Feb; 11(2):101-6. PubMed ID: 12560938 [TBL] [Abstract][Full Text] [Related]
8. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592 [TBL] [Abstract][Full Text] [Related]
9. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Ringdén OT; Le Blanc K; Remberger M Exp Hematol; 2005 May; 33(5):505-12. PubMed ID: 15850828 [TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs. Kaito K; Kobayashi M; Sakamoto M; Shimada T; Masuoka H; Nishiwaki K; Saeki A; Sekita T; Otsubo H; Hosoya T Acta Haematol; 1998; 100(1):57-60. PubMed ID: 9691149 [TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519 [TBL] [Abstract][Full Text] [Related]
12. Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin. Grassinger J; Mueller G; Hart C; Nilsson SK; Haylock DN; Andreesen R; Hennemann B Eur J Haematol; 2008 Jan; 80(1):20-30. PubMed ID: 18028434 [TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Johnston EM; Crawford J Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594 [TBL] [Abstract][Full Text] [Related]
14. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. Ohno R; Miyawaki S; Hatake K; Kuriyama K; Saito K; Kanamaru A; Kobayashi T; Kodera Y; Nishikawa K; Matsuda S; Yamada O; Omoto E; Takeyama H; Tsukuda K; Asou N; Tanimoto M; Shiozaki H; Tomonaga M; Masaoka T; Miura Y; Takaku F; Ohashi Y; Motoyoshi K J Clin Oncol; 1997 Aug; 15(8):2954-65. PubMed ID: 9256140 [TBL] [Abstract][Full Text] [Related]
15. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124 [TBL] [Abstract][Full Text] [Related]
16. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy. de Haan G; Engel C; Dontje B; Loeffler M; Nijhof W Cancer Res; 1995 Jan; 55(2):324-9. PubMed ID: 7529132 [TBL] [Abstract][Full Text] [Related]
17. [The use of erythropoietin alpha in programs of high-dose chemotherapy]. Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490 [TBL] [Abstract][Full Text] [Related]
18. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929 [TBL] [Abstract][Full Text] [Related]
19. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors. Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449 [TBL] [Abstract][Full Text] [Related]
20. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]